We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Hyundai Bioscience

News List

Hyundai Bioscience finds combination therapy effective against Covid-19 Pharmaceutical-Technology
December 09, 2021
Hyundai Bioscience has reported that a combination of the niclosamide-based oral antiviral drug candidate, CP-COV03, with anti-inflammatory therapy, dexamethasone, showed to be effective in people with severe Covid-19 in a study.
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19 prnasia
December 23, 2020
Hyundai Bioscience announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of COVID-19.
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem prnewswire
December 09, 2020
Hyundai Bioscience released a report on December 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single ...